Beta-secretase (BACE)

Lanabecestat camsylate is a potent, orally active inhibitor of beta-secretase 1 (BACE1), demonstrating a Ki value of 0.4 nM. This compound effectively penetrates the blood-brain barrier, making it an essential tool for investigating the pathophysiology of Alzheimer's disease. Lanabecestat camsylate is utilized in research aimed at understanding the therapeutic potential of BACE1 inhibition in neurodegenerative conditions.

BACE-IN-3 is a selective inhibitor of beta-secretase (BACE) with an IC50 of 0.004 μM. This compound plays a critical role in the modulation of amyloid-beta peptide production, making it a valuable tool for research in Alzheimer's disease and related neurodegenerative disorders. Its potent inhibitory activity against BACE makes it suitable for studying the mechanisms of amyloidogenic processes and evaluating potential therapeutic strategies.

BACE1-IN-11 is a potent inhibitor of beta-secretase 1 (BACE1), exhibiting an IC50 value of 72 μM. This compound has been identified as a valuable tool for Alzheimer's disease research, specifically in the study of amyloid precursor protein processing and beta-amyloid peptide generation. Through its selective inhibition of BACE1, BACE1-IN-11 aids in exploring therapeutic strategies aimed at mitigating the impact of Alzheimer's pathology.

GRL-8234 is a potent β-secretase (BACE1) inhibitor with a high affinity for its target (Ki = 1.8 nM) and the ability to penetrate the blood-brain barrier. This compound has demonstrated efficacy in rescuing age-related cognitive decline in Tg2576 mice, making it a valuable tool for Alzheimer's disease research. GRL-8234 is suitable for investigations focused on the mechanisms of AD and potential therapeutic interventions.

β-Secretase Inhibitor III is a highly selective inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), with a Ki value of 0.13 nM. This compound effectively reduces the production of amyloid-beta peptides, making it a valuable tool for research on Alzheimer's disease and related neurodegenerative disorders. Its specificity for BACE1 allows for precise investigations into amyloid pathology and the development of therapeutics targeting this crucial step in amyloidogenesis.

OM99-2 is a potent peptidomimetic inhibitor of human brain memapsin 2, exhibiting a tight-binding affinity with a Ki value of 9.58 nM. This compound plays a crucial role in the advancement of BACE1 inhibitor research and has significant implications in the study of Alzheimer's disease. OM99-2 is valuable for investigating the pathogenic mechanisms of neurodegenerative disorders and may contribute to the development of therapeutic strategies.

β-Secretase Inhibitor II is a potent inhibitor of β-Secretase, designed to impede the enzyme's activity in the amyloidogenic pathway. It has an IC50 value of 700 nM for total Aβ inhibition and an IC50 of 2.5 μM for the specific inhibition of Aβ1–42. This compound is valuable for research into Alzheimer's disease and the mechanisms underlying amyloid plaque formation.

Lanabecestat hydrochloride is a potent inhibitor of beta-secretase (BACE1), primarily employed in the research of Alzheimer's disease. This compound effectively reduces amyloid beta peptide concentrations in plasma, cerebrospinal fluid, and brain tissue in a dose- and time-dependent manner. While demonstrating a reduction in Aβ neuritic plaque burden, lanabecestat has not shown clinical benefits or the ability to slow Alzheimer's disease progression. It serves as a valuable tool for studying the mechanisms underlying amyloid pathology and evaluating potential therapeutic approaches.

BACE1-IN-9 is a potent inhibitor of β-site APP cleaving enzyme 1 (BACE1), exhibiting an IC50 of 1.2 µM. This compound is significant in the context of Alzheimer's disease research, as it inhibits the cleavage of amyloid precursor protein, thereby potentially reducing amyloid beta production. BACE1-IN-9 can be utilized in studies aimed at elucidating the role of BACE1 in neurodegeneration and assessing therapeutic approaches for Alzheimer's disease.

AZ-4217 is a potent inhibitor of β-site amyloid precursor protein cleavage enzyme 1 (BACE1), exhibiting an IC50 of 160 pM in human SH-SY5Y cells. This compound effectively reduces amyloid deposition in Tg2576 mouse models, making it a valuable tool for Alzheimer’s Disease research and related neurodegenerative studies. Its ability to modulate BACE1 activity underscores its potential significance in therapeutic applications targeting amyloid pathology.

Verubecestat tosylate is a potent inhibitor of BACE1 and BACE2, displaying high affinity with Ki values of 2.2 nM and 0.38 nM, respectively. This compound effectively reduces levels of Aβ40, making it a potential therapeutic agent for Alzheimer's Disease research. Verubecestat tosylate is utilized in studies exploring the modulation of amyloid-beta peptide production and its implications in neurodegenerative disorders.

SEVNLDAEFR is a specific substrate for the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). This peptide is utilized in biochemical assays to study BACE1 activity and amyloid beta peptide generation, which are crucial in Alzheimer's disease research. Its application in research facilitates the investigation of potential therapeutic strategies targeting BACE1-mediated pathways.

SEW06622 is a selective inhibitor of beta-secretase 1 (BACE-1) with an IC50 value of 6.3 μM. This compound plays a crucial role in Alzheimer's disease research by modulating amyloid precursor protein processing, thereby reducing amyloid-beta plaque formation. SEW06622 is valuable for studies focused on neurodegenerative processes and therapeutic interventions in Alzheimer's disease.

PF-06663195 is a selective β-secretase 1 (BACE1) inhibitor, exhibiting IC50 values of 53 nM for the BACE1 CFA assay and 15 nM for the BACE1 WCA assay. This compound is a valuable tool for investigating the role of BACE1 in the pathogenesis of Alzheimer’s disease and can aid in the discovery of potential therapeutic strategies targeting amyloid precursor protein processing.

BACE-IN-1 is a selective β-secretase inhibitor, designed to target the β-site amyloid precursor protein cleaving enzyme (BACE). By inhibiting BACE activity, this compound has potential applications in the treatment of Alzheimer's disease and other disorders associated with amyloid plaque formation. Its unique imidazo[1,2-a]pyridine structure enhances its efficacy in this specific biological context.